Cartesian Therapeutics Inc (RNAC)

Dec 21, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 21, 2024

Dec 21, 2024

BNP Paribas Financial Markets Has $27,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Dec 21, 2024

Dec 20, 2024

Cartesian Therapeutics initiated with a Buy at BTIG - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

BTIG Research Begins Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Dec 19, 2024

Dec 19, 2024

BTIG initiates Buy rating on Cartesian Therapeutics stock highlighting mRNA CAR-T potential - Investing.com

Dec 19, 2024

Dec 18, 2024

Cartesian Therapeutics Announces New Employment Inducement Grants - Barchart

Dec 18, 2024

Dec 18, 2024

Cartesian Therapeutics Awards Key Talent with mRNA Cell Therapy Stock Options in Strategic Growth Move - StockTitan

Dec 18, 2024

Dec 08, 2024

Fmr LLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Dec 08, 2024

Dec 08, 2024

Fmr LLC Has $45.97 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Dec 08, 2024

Dec 06, 2024

HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Dec 06, 2024

Dec 05, 2024

Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Produces Durable Responses in Myasthenia Gravis - CGTLive™

Dec 05, 2024

Dec 05, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Earns “Buy” Rating from Needham & Company LLC - Defense World

Dec 05, 2024

Dec 04, 2024

Analysts Issue Forecasts for RNAC FY2024 Earnings - MarketBeat

Dec 04, 2024

Dec 04, 2024

Moving into Phase III, Cartesian data show momentum - The Pharma Letter

Dec 04, 2024

Dec 04, 2024

Cartesian Therapeutics Reports Promising Phase 2b Trial Results - Yahoo Finance

Dec 04, 2024

Dec 04, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World

Dec 04, 2024

Dec 03, 2024

Cartesian Therapeutics Announces Positive Updated Results - GlobeNewswire

Dec 03, 2024

Dec 03, 2024

Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis Treatment - StockTitan

Dec 03, 2024

Nov 29, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.33 Consensus Price Target from Brokerages - Defense World

Nov 29, 2024

Nov 27, 2024

Great Point Partners LLC Invests $3.22 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Nov 27, 2024

Nov 27, 2024

Needham & Company LLC Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Nov 27, 2024

Nov 26, 2024

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.33 - MarketBeat

Nov 26, 2024

Nov 25, 2024

Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 25, 2024

Nov 22, 2024

Cartesian therapeutics CTO sells $649,029 in stock By Investing.com - Investing.com Nigeria

Nov 22, 2024

Nov 22, 2024

Cartesian therapeutics CTO sells $649,029 in stock - Investing.com India

Nov 22, 2024

Nov 21, 2024

Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire

Nov 21, 2024

Nov 21, 2024

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - The Manila Times

Nov 21, 2024

Nov 21, 2024

Cartesian Therapeutics to Present Key Phase 2b Trial Data for Myasthenia Gravis Treatment | RNAC Stock News - StockTitan

Nov 21, 2024

Nov 21, 2024

Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St

Nov 21, 2024

Nov 19, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat

Nov 19, 2024

Nov 19, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million By Investing.com - Investing.com Nigeria

Nov 19, 2024

Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com

Nov 18, 2024

Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com

Nov 18, 2024

Nov 18, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com

Nov 18, 2024

Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock - Investing.com

Nov 18, 2024

Nov 17, 2024

Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 17, 2024

Nov 14, 2024

Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 13, 2024

Nov 12, 2024

HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World

Nov 12, 2024

Nov 11, 2024

Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World

Nov 11, 2024

Nov 10, 2024

Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha

Nov 10, 2024

Nov 09, 2024

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat

Nov 09, 2024

Nov 09, 2024

Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com

Nov 09, 2024

Nov 08, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 08, 2024

Nov 08, 2024

Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan

Nov 08, 2024

Nov 07, 2024

Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz

Nov 07, 2024